抗苗勒管激素与抑制素B对多囊卵巢综合征的临床预测价值

doi:10.3969/j.issn.1006-7795.2017.04.002

首都医科大学学报 ›› 2017, Vol. 38 ›› Issue (4): 492-497.doi: 10.3969/j.issn.1006-7795.2017.04.002

抗苗勒管激素与抑制素B对多囊卵巢综合征的临床预测价值

王虎生¹, 阮祥燕^1,2, 李雪¹, 赵越¹, 李扬璐¹, 谷牧青¹, 杜娟¹, 宋菁华¹, 金凤羽¹, Alfred O. Mueck^1,2

1. 首都医科大学附属北京妇产医院妇科内分泌科, 北京 100026;
2. 德国图宾根大学妇产医院内分泌与绝经中心, 图宾根 D-72076, 德国

收稿日期:2017-06-05 出版日期:2017-07-21 发布日期:2017-07-20
通讯作者: 阮祥燕 E-mail:ruanxiangyan@163.com
基金资助:
首都临床特色应用研究与成果推广（Z161100000516143），首都卫生发展科研专项项目（2016-2-2113），北京市医院管理局临床技术创新项目（XMLX201710），北京市卫生系统高层次卫生技术人才（学科带头人）（2014-2-016），国家外国专家局2017年度北京市引进国外技术、管理人才项目（20171100004）

Clinical predictive value of anti-Müllerian hormone and inhibin B in polycystic ovary syndrome

Wang Husheng¹, Ruan Xiangyan^1,2, Li Xue¹, Zhao Yue¹, Li Yanglu¹, Gu Muqing¹, Du Juan¹, Song Jinghua¹, Jin Fengyu¹, Alfred O. Mueck^1,2

1. Department of Gynecological Endocrinology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing 100026, China;
2. Section of Endocrinology and Menopause, Department of Women's Health, University of Tubingen, Tubingen D-72076, Germany

Received:2017-06-05 Online:2017-07-21 Published:2017-07-20
Supported by:
This study was supported by Capital Characteristic Clinic Project of China(Z161100000516143); Beijing Capital Foundation for Medical Science Development and Research(2016-2-2113); Clinical Technique Innovation Project of Beijing Municipal Administration of Hospitals(XMLX201710); Beijing Municipality Health Technology High-level Talent(2014-2-016);Foreign Technical and Administrative Talent Introduction Project in 2017, State Administration of Foreign Experts Affairs of China(20171100004)

摘要/Abstract

摘要： 目的通过分析多囊卵巢综合征（polycystic ovary syndrome，PCOS）病人与对照组的抑制素B（inhibin B，INHB）、抗苗勒管激素（anti-Müllerian hormone，AMH）及各项内分泌指标，探讨INHB、AMH对PCOS的临床预测价值及比较两组内分泌指标的特点。方法选取2016年9月至2017年5月间在首都医科大学附属北京妇产医院内分泌科就诊的PCOS 病人567 例为研究组，取同期就诊的年龄、原发不孕与继发不孕病人或正常体检者53例作为对照组。测量所有参与者的身高、体质量，空腹抽血查INHB、AMH、卵泡刺激素（follicle-stimulating hormone，FSH）、黄体生成素（luteinizing hormone，LH）、雌二醇（estradiol，E₂）、睾酮（testosterone，T），分析PCOS组与对照组的血清INHB、AMH质量浓度及内分泌指标特点。结果 PCOS 组的血清AMH 质量浓度、LH、T、体质量指数（body mass index，BMI）均明显高于对照组，E₂、FSH/LH低于对照组，且组间差异均有统计学意义（P<0.05）。PCOS组的INHB质量浓度高于对照组，FSH低于对照组，组间差异均无统计学意义（P>0.05）。AMH预测多囊卵巢综合征的最佳分界值（cut-off）值为4.84 μg/L，敏感度为84.48%，特异度为69.81%。INHB预测多囊卵巢综合征的cut-off 值为70.8 ng/L，敏感度为53.97%，特异度为67.92%，AMH与INHB联合预测（并联试验）多囊卵巢综合征的敏感度为90.29%，特异度为54.92%。结论 AMH预测PCOS的cut-off 值为4.84 μg/L，INHB预测PCOS的cut-off 值为70.8 ng/L，且AMH与INHB的联合检测（并列试验）敏感度高于AMH单项检测，这对临床PCOS的预测有很重要的指导意义。

关键词: 多囊卵巢综合征, 抗苗勒管激素, 抑制素B, 联合检测

Abstract: Objective The present study aimed to investigate the effects of inhibin B (INHB), anti-Mullerian hormone (AMH) and various endocrine indicators in patients with polycystic ovary syndrome (PCOS) and control group, and to explore the clinical predictive value of INHB and AMH and compare the characteristics of endocrine indexes in two groups.Methods A total of 567 PCOS patients and 53 normal subjects as a control group were enrolled. Fasting blood samples for hormones ［anti-Müllerian hormone(AMH), inhibinB(INHB), follicle-stimulating hormone (FSH),luteinizing hormone (LH), estradiol (E₂) and testosterone (T)］ were measured. Results The AMH concentration, LH, T and body mass index (BMI) in PCOS group were significantly higher than those in control group. The E₂ and FSH/LH were lower than those in control group, and the difference was statistically significant (P<0.05). The concentration of INHB in PCOS group was higher than that in control group, FSH level was lower than that in control group, and there was no significant difference between the two groups (P> 0.05). Receiver operating characteristic (ROC) curve analysis of serum AMH and INHB in prediction of PCOS showed that the area under the ROC curve (AUC) value of the serum AMH level was 0.814, with a cut-off value of 4.84 μg/L. The sensitivity and specificity were 84.48% and 69.81%, respectively. The AUC value of serum INHB was 0.575, with a cut-off value of 70.8 ng/L, and the sensitivity and specificity were 53.97% and 67.92%, respectively. AMH and INHB combined prediction (Parallel Test) polycystic ovary syndrome sensitivity was 90.29%, specificity was 54.92%. Conclusion The cut-off value of AMH predicted PCOS was 4.84 μg/L, and the cut-off value of INHB predicted PCOS was 70.8 ng/L. The sensitivity of combined detection (Parallel Test)of AMH and INHB was higher than that of AMH single test. The prediction of PCOS will have a very important guiding significance.

Key words: polycystic ovary syndrome, anti-Müllerian hormone, inhibin B, combined detection

中图分类号:

R711.75

王虎生, 阮祥燕, 李雪, 赵越, 李扬璐, 谷牧青, 杜娟, 宋菁华, 金凤羽, Alfred O. Mueck. 抗苗勒管激素与抑制素B对多囊卵巢综合征的临床预测价值[J]. 首都医科大学学报, 2017, 38(4): 492-497.

Wang Husheng, Ruan Xiangyan, Li Xue, Zhao Yue, Li Yanglu, Gu Muqing, Du Juan, Song Jinghua, Jin Fengyu, Alfred O. Mueck. Clinical predictive value of anti-Müllerian hormone and inhibin B in polycystic ovary syndrome[J]. Journal of Capital Medical University, 2017, 38(4): 492-497.

参考文献

[1] Conway G, Dewailly D, Diamanti-Kandarakis E, et al. The polycystic ovarysyndrome: a position statement from the European Society of Endocrinology[J]. Eur J Endocrinol, 2014,171(4):1-29.
[2] Hart R, Doherty D A, Mori T, et al. Extent of metabolic risk inadolescent girls with features of polycystic ovary syndrome[J].Fertil Steril,2011,95(7):2347-2353.
[3] Li H W, Lee V C, Lau EY, et al. Role of baseline antral follicle countand anti-mullerian hormone in prediction of cumulative live birth inthe first in vitro fertilisation cycle: a retrospective cohort analysis[J]. PLoS One, 2013, 8(4): e61095.
[4] Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group.Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome(PCOS) [J]. Hum Reprod, 2004, 19(1): 41-47.
[5] 黄月勤. 临床流行病学[M]. 北京: 人民卫生出版社, 2014:157-160.
[6] 余松林. 医学统计学[M]. 北京:人民卫生出版社,2002:164-178.
[7] Dursun F, Güven A, Yildiz M. Assessment of anti-müllerianHormone level in management of Adolescents withPolycystic ovary syndrome[J]. J Clin Res Pediatr Endocrinol, 2016,8(1):55-60.
[8] Pawelczak M, Kenigsberg L, Milla S, et al. Elevated serum anti-Müllerian hormone in adolescentswithpolycystic ovary syndrome: relationship toultrasoundfeatures[J].J Pediatr Endocrinol Metab, 2012,25(9-10):983-989.
[9] Cassar S, Teede H J, Moran L J, et al. Polycystic ovary syndromeand anti-Müllerian hormone: role of insulin resistance,androgens, obesity and gonadotrophins[J]. ClinEndocrinol:Oxf, 2014, 81(6):899-906.
[10] Roberts V J, Barth S, el-Roeiy A, et al. Expression of inhibin/activin subunits and follistatin messenger ribonucleic acids and proteins in ovarian follicles and the corpus luteum during the human menstrual cycle[J]. J Clin Endocrinol Metab, 1993, 77(5): 1402-1410.
[11] Aylin Y, Çaðcil Y, Firdevs B, et al. Anti-müllerian hormone and lnhibin-A, but not inhibin-B or insulin like peptide-3, may be used as surrogates in the diagnosis of polycystic ovary syndrome in adolescents: preliminary results[J]. J Clin Res Pediatr Endocrinol 2016,8(3):288-297.
[12] Magoffin D A, Jakimiuk A J. Inhibin A, inhibin B and activinA concentrations in follicular fluid from women withpolycystic ovary syndrome[J]. Hum Reprod,1998, 13(10):2693-2698.
[13] Lockwood G M, Muttukrishna S, Groome N P, et al. Mid-follicular phase pulses of inhibin Bare absent in polycystic ovarian syndrome and are initiatedby successful laparoscopic ovarian diathermy: a possiblemechanism regulating emergence of the dominant follicle[J].J Clin Endocrinol Metab, 1998, 83(5):1730-1735.
[14] Laven J S, Imani B, Eijkemans M J, et al.Absent biologically relevant associations between serum inhibin B concentrations and characteristics of polycystic ovary syndrome in normogonadotrophic anovulatory infertility[J]. Hum Reprod,2001, 16(7):1359-1364.
[15] Welt C K, Taylor A E, Martin K A,et al. Serum inhibin Bin polycystic ovary syndrome: regulation by insulin andluteinizing hormone[J]. J Clin Endocrinol Metab, 2002, 87(12):5559-5565.
[16] Hazout A, Bouchard P, Seifer D B, et al. Serumanti-mullerian hormone/mullerian-inhibiting substanceappears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulatinghormone, inhibin B, or estradiol[J]. Fertil Steril,2004,82(5):1323-1329.
[17] Lambalk C B, Van Disseldorp J, de Koning C H, et al.Testing ovarian reserve to predict age at menopause[J]. Maturitas, 2009,63(4):280-291.
[18] Pellatt L, Rice S, Mason H D. Anti-Müllerian hormone and polycystic ovary-syndrome: a mountain too high？[J]. Reproduction,2010,139(5):828-833.
[19] 田玄玄,阮祥燕,王娟,等.437例多囊卵巢综合征相关因素调查分析[J].首都医科大学学报,2014,35(4):414-418.
[20] 杨颖, 王金敏,彭书苹,等.肥胖型多囊卵巢综合征病人临床特征分析[J].中国煤炭工业医学杂志,2014,17(9):1453-1455.

抗苗勒管激素与抑制素B对多囊卵巢综合征的临床预测价值

Clinical predictive value of anti-Müllerian hormone and inhibin B in polycystic ovary syndrome

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	李健, 白文佩, 江波, 白栎然, 吴凤云. 生酮饮食对超重/肥胖多囊卵巢综合征女性月经及生育力的影响[J]. 首都医科大学学报, 2021, 42(6): 1021-1025.
[2]	王虎生, 阮祥燕, 程姣姣, Alfred O. Mueck. 肥胖型多囊卵巢综合征的氧化应激与脂代谢关系的研究[J]. 首都医科大学学报, 2021, 42(4): 540-546.
[3]	杨瑜, 阮祥燕, 鞠蕊, 许新, 谷牧青, 程姣姣. 屈螺酮炔雌醇Ⅱ对多囊卵巢综合征患者血清抗苗勒管激素的影响[J]. 首都医科大学学报, 2021, 42(4): 547-552.
[4]	刘真, 殷冬梅, 战思恩, 阮祥燕. 黄连素改善多囊卵巢综合征患者代谢异常的系统评价[J]. 首都医科大学学报, 2021, 42(4): 588-595.
[5]	王景尚, 尹晓丹, 何军琴, 武颖, 张莹, 李宪锐. 来曲唑联合高糖高脂饮食构建多囊卵巢综合征伴胰岛素抵抗大鼠模型研究[J]. 首都医科大学学报, 2021, 42(3): 436-442.
[6]	张黎锐, 郑薇, 刘程, 梁馨, 张莉, 田志红, 李光辉. 多囊卵巢综合征孕妇妊娠期增重模式与母儿结局的关系[J]. 首都医科大学学报, 2021, 42(2): 169-176.
[7]	闵敏, 阮祥燕, 王虎生, 程姣姣, 罗穗豫, 许仲婷, 李萌, Alfred O. Mueck. 奥利司他综合干预对超重或肥胖型多囊卵巢综合征患者代谢综合征及其组分的影响[J]. 首都医科大学学报, 2020, 41(4): 514-519.
[8]	王宾红, 阮祥燕, 鞠蕊, 豆竹丽, 秦爽, 张露平, 许新, 杨瑜, Alfred O. Mueck. 综合干预治疗对多囊卵巢综合征患者雄激素浓度的影响[J]. 首都医科大学学报, 2020, 41(4): 520-524.
[9]	豆竹丽, 阮祥燕, 鞠蕊, 王宾红, 秦爽, 许新, 杨瑜, 张露平. 综合干预后多囊卵巢综合征不孕患者应用来曲唑促排卵的临床效果[J]. 首都医科大学学报, 2020, 41(4): 525-529.
[10]	秦爽, 阮祥燕, 王宾红, 鞠蕊, 张露平, 豆竹丽, 程姣姣, 金婧. 多囊卵巢综合征患者促排卵周期中成熟卵泡性激素浓度对妊娠的影响[J]. 首都医科大学学报, 2020, 41(4): 530-535.
[11]	阮祥燕, 张露平, 代荫梅, 王虎生, 金凤羽, 谷牧青, 程姣姣, 鞠蕊, 闵敏, Thomas Roemer. 门诊微型宫腔镜检查在不孕症患者中的临床应用[J]. 首都医科大学学报, 2019, 40(4): 549-553.
[12]	谷牧青, 李扬璐, 程姣姣, 王虎生, 阮祥燕, 贾婵维. 达英-35对多囊卵巢综合征患者代谢与性激素的影响[J]. 首都医科大学学报, 2019, 40(4): 560-565.
[13]	闵敏, 阮祥燕, 赵越, 王虎生, 程姣姣, 罗穗豫, 许仲婷, 李萌, 张露平, 王月姣, Alfred O. Mueck. 奥利司他综合干预对超重或肥胖型PCOS患者雄激素及糖脂代谢的影响[J]. 首都医科大学学报, 2019, 40(4): 572-577.
[14]	杜娟, 阮祥燕, Alfred O. Mueck. 口服避孕药对多囊卵巢综合征患者性功能的影响[J]. 首都医科大学学报, 2018, 39(4): 499-504.
[15]	金婧, 阮祥燕, 华琳, 李杨璐, 王利娟, 王虎生, 赵越, Alfred O. Mueck. 多囊卵巢综合征卵巢储备功能降低患者肥胖及糖脂代谢特征[J]. 首都医科大学学报, 2018, 39(4): 505-511.